Frequently Asked Questions
Find answers to the most common questions about retatrutide, including how it works, current clinical trial status, safety information, and availability. All answers are based on published scientific evidence.
General Questions About Retatrutide
Frequently asked questions about what retatrutide is, who is developing it, and its current status.
What is retatrutide?
Retatrutide (LY3437943) is an investigational medication developed by Eli Lilly and Company. It is a single peptide molecule that simultaneously activates three metabolic hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple receptor agonism is a novel approach designed to address obesity and type 2 diabetes through complementary metabolic pathways.
Is retatrutide FDA-approved?
No. As of early 2025, retatrutide is an investigational compound in Phase 3 clinical development. It has not been approved by the FDA or any other regulatory authority worldwide. It is not available for prescription or commercial purchase. Any legitimate use is limited to authorized clinical trials.
Who is developing retatrutide?
Retatrutide is being developed by Eli Lilly and Company, a major pharmaceutical company based in Indianapolis, Indiana. Lilly also developed tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity), which is a related dual GIP/GLP-1 receptor agonist.
What does LY3437943 mean?
LY3437943 is retatrutide's development code assigned by Eli Lilly. The 'LY' prefix identifies it as a Lilly compound, and the numerical designation is its internal identifier. 'Retatrutide' is the drug's International Nonproprietary Name (INN), which is the standardized name for scientific and medical communication.
What conditions is retatrutide being studied for?
Retatrutide is primarily being studied for the treatment of obesity and type 2 diabetes in the Phase 3 TRIUMPH clinical program. The Phase 2 data also showed significant liver fat reduction, which has generated interest in its potential for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though a dedicated liver disease Phase 3 program has not been publicly announced.
How is retatrutide different from semaglutide or tirzepatide?
Semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor. Tirzepatide (Mounjaro/Zepbound) targets both GIP and GLP-1 receptors. Retatrutide targets all three: GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure and promote liver fat reduction, which are effects not available from single or dual agonists.
Does retatrutide have a brand name?
No. Retatrutide does not have a brand name because it has not received marketing authorization from any regulatory agency. Brand names are typically assigned during the regulatory approval process. The drug is referred to by its INN (retatrutide) or development code (LY3437943) in scientific literature.
When might retatrutide be available?
Specific timelines are uncertain and depend on Phase 3 trial outcomes, regulatory submissions, and agency review times. Based on typical development timelines and assuming positive Phase 3 results, regulatory submissions could potentially occur around 2026-2027, with possible approval in the 2027-2028 timeframe. These are estimates, not commitments from Eli Lilly or regulatory agencies.
How Retatrutide Works
Frequently asked questions about retatrutide's mechanism of action, including its triple receptor agonism and how it differs from other metabolic therapies.
What does 'triple agonist' mean?
A triple agonist is a single molecule that activates three different receptor types. Retatrutide activates GIP receptors, GLP-1 receptors, and glucagon receptors. Each receptor triggers different biological effects, and their simultaneous activation produces complementary metabolic benefits that are hypothesized to be greater than any single receptor pathway alone.
What does GLP-1 receptor activation do?
GLP-1 receptor activation reduces appetite through effects on brain satiety centers, stimulates insulin secretion in a glucose-dependent manner (lowering blood sugar without causing dangerous drops), suppresses glucagon release from the pancreas, and slows gastric emptying. This is the same mechanism used by approved drugs like semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda).
What does GIP receptor activation do?
GIP receptor activation enhances insulin secretion, influences adipose (fat) tissue function, and may contribute to appetite suppression through brain pathways. When combined with GLP-1 receptor activation, GIP appears to amplify the metabolic benefits, as demonstrated by tirzepatide (Mounjaro/Zepbound), which targets both GIP and GLP-1 receptors.
What does glucagon receptor activation do?
Glucagon receptor activation increases energy expenditure (the number of calories the body burns at rest) and promotes fatty acid oxidation in the liver (burning stored fat for energy). This component is unique to retatrutide among advanced clinical candidates and is thought to explain the enhanced weight loss and dramatic liver fat reduction observed in clinical trials.
Why doesn't the glucagon component raise blood sugar?
Glucagon naturally raises blood glucose by stimulating the liver to release stored sugar. In retatrutide, this glucose-raising effect is counterbalanced by the simultaneous GLP-1 and GIP receptor activation, which promote insulin secretion and suppress excessive glucagon signaling. Clinical trial data confirm that the net effect is improved, not worsened, blood sugar control.
Why is retatrutide given once weekly?
Retatrutide's peptide structure includes a fatty acid modification that allows it to bind to albumin, a protein in the blood. This albumin binding protects the drug from being broken down quickly and extends its half-life to approximately six days, meaning that a single injection provides sustained drug levels throughout a full week.
How does retatrutide cause weight loss?
Retatrutide promotes weight loss through two complementary mechanisms: reducing caloric intake (through appetite suppression mediated by GLP-1 and GIP receptor activation in the brain) and increasing caloric expenditure (through energy expenditure increases driven by glucagon receptor activation). This dual approach to the energy balance equation distinguishes it from single- and dual-agonist therapies that primarily reduce intake.
Clinical Trials
Frequently asked questions about retatrutide's clinical trial program, including Phase 2 results and the ongoing Phase 3 TRIUMPH studies.
What clinical trials have been completed for retatrutide?
As of early 2025, retatrutide has completed Phase 1 (first-in-human safety and PK study) and Phase 2 clinical trials. The Phase 2 program included a 48-week obesity trial (NCT04881706, published in the New England Journal of Medicine) and a 36-week type 2 diabetes trial (NCT04867785, published in The Lancet). Both produced positive results that supported advancement to Phase 3.
What were the main results of the Phase 2 obesity trial?
The Phase 2 obesity trial demonstrated mean weight loss of up to 24.2% at 48 weeks in the highest dose group (12 mg), with 100% of participants at that dose losing at least 5% of body weight. The trial also showed an approximately 82% relative reduction in liver fat, improvements in blood pressure and lipids, and a manageable gastrointestinal side effect profile. These were the highest weight loss results ever reported for a pharmacological agent.
What were the main results of the Phase 2 diabetes trial?
The Phase 2 type 2 diabetes trial showed HbA1c reductions of up to 2.02 percentage points at 36 weeks in the highest dose group. Approximately 95% of participants at the highest dose achieved an HbA1c below 7.0% (the standard treatment target), and approximately 62% reached HbA1c below 5.7% (the non-diabetic range). Retatrutide at higher doses significantly outperformed the active comparator, dulaglutide 1.5 mg.
What is the TRIUMPH program?
TRIUMPH (Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health) is the Phase 3 clinical development program for retatrutide. It includes TRIUMPH-1 (the pivotal obesity trial) and TRIUMPH-2 (the pivotal type 2 diabetes trial), along with potentially other studies. These large-scale trials will provide the definitive data needed for regulatory approval decisions.
When will Phase 3 results be available?
Specific timelines depend on enrollment progress and other factors, but Phase 3 primary results are generally expected in the 2025-2027 timeframe. Phase 3 obesity trials typically require 68-72 weeks of treatment, followed by data analysis and reporting. Eli Lilly has not publicly committed to specific readout dates.
Can I participate in a retatrutide clinical trial?
This resource does not facilitate clinical trial enrollment. If you are interested in participating in a clinical trial, discuss this with your healthcare provider or search for registered studies on ClinicalTrials.gov using the search term 'retatrutide' or 'LY3437943'. Eligibility criteria vary by trial and are determined by the study investigators.
Safety Questions
Frequently asked questions about the safety profile of retatrutide, including side effects observed in clinical trials and outstanding safety questions.
What are the most common side effects of retatrutide?
In Phase 2 clinical trials, the most commonly reported side effects were gastrointestinal in nature: nausea, diarrhea, vomiting, constipation, and decreased appetite. These effects are consistent with the known pharmacology of GLP-1 receptor agonists and were predominantly mild to moderate in severity. Most GI events occurred during the dose-escalation period and diminished over time as participants adapted to the medication.
How many people stopped taking retatrutide due to side effects?
In the Phase 2 obesity trial, treatment discontinuation due to adverse events ranged from approximately 0% at the lowest dose (1 mg) to approximately 16% at the highest dose (12 mg). These rates were driven primarily by gastrointestinal intolerance and are within the range observed for other incretin-based therapies. Gradual dose escalation was shown to improve tolerability compared to fixed-dose starts.
Does retatrutide cause hypoglycemia (low blood sugar)?
In the Phase 2 obesity trial (participants without diabetes), no significant hypoglycemia was reported. In the type 2 diabetes trial, hypoglycemia rates were low and were primarily associated with concomitant use of other diabetes medications (such as sulfonylureas) that can independently cause low blood sugar. Retatrutide's insulin-promoting effects are glucose-dependent, meaning they are activated mainly when blood sugar is elevated, which inherently reduces hypoglycemia risk.
Are there any heart-related concerns?
Retatrutide was associated with a modest increase in resting heart rate (approximately 2-4 beats per minute), which is a known class effect of GLP-1 receptor agonists. Blood pressure and lipid profiles improved with treatment, which are favorable cardiovascular signals. However, no dedicated cardiovascular outcomes trial has been completed for retatrutide, so definitive cardiovascular safety or benefit data are not yet available.
What about long-term safety?
The longest published treatment duration for retatrutide is 48 weeks from the Phase 2 obesity trial. Long-term safety data over multiple years, which are essential for a medication intended for chronic use, will be generated by the Phase 3 TRIUMPH program and post-marketing surveillance if the drug is approved. Long-term effects on bone density, muscle mass, nutritional status, and organ function require continued study.
Were there any serious safety signals in clinical trials?
No unexpected serious safety signals were reported in the Phase 2 retatrutide trials. The overall safety profile was consistent with the known effects of incretin-based therapies. However, Phase 2 trials are relatively small (hundreds of participants) and may not detect uncommon adverse events that only become apparent with larger populations. Phase 3 trials will provide a more comprehensive safety assessment.
Availability and Approval
Frequently asked questions about when retatrutide might be available, regulatory approval timelines, and current access options.
When will retatrutide be available?
Retatrutide is not currently available for prescription or purchase. It is in Phase 3 clinical development, which must be completed before regulatory submissions can be made. Based on typical development timelines and assuming positive Phase 3 outcomes, regulatory submissions could potentially occur around 2026-2027, with possible approval in the 2027-2028 timeframe. These are estimates and are subject to change based on trial outcomes and regulatory processes.
Can I get retatrutide now?
The only legitimate way to receive retatrutide currently is through participation in an authorized clinical trial. The drug is not approved for prescription, and purchasing it outside of a clinical trial setting is not sanctioned by regulatory authorities. We strongly advise against obtaining any investigational compound through unregulated channels.
Will retatrutide be a pill or injection?
In all clinical trials to date, retatrutide has been administered as a once-weekly subcutaneous injection. If approved, it is expected to be available initially as an injectable formulation. Whether an oral formulation might be developed in the future is unknown and would require separate clinical development.
How much will retatrutide cost?
Pricing has not been determined, as retatrutide has not been approved for marketing. For context, other incretin-based obesity medications (semaglutide, tirzepatide) carry list prices in the range of approximately $1,000-$1,300 per month in the United States, though net prices after insurance and rebates vary widely. Retatrutide pricing will depend on its approved indications, competitive positioning, insurance coverage decisions, and Eli Lilly's pricing strategy.
Will insurance cover retatrutide?
Insurance coverage decisions cannot be predicted at this time. Coverage for obesity medications has historically been limited, though it has been expanding in recent years as the medical community increasingly recognizes obesity as a chronic disease requiring pharmacological treatment. Coverage will depend on the approved indications, individual insurance plans, and payer policies at the time of potential approval.
Will retatrutide be available outside the United States?
If retatrutide receives FDA approval, Eli Lilly would be expected to pursue regulatory submissions in other major markets, including the European Union (through the EMA), Japan, Canada, Australia, and other countries. International approval timelines typically lag behind U.S. approval by 6-18 months, depending on the regulatory agency and submission timing.